Abstract Human cd T cells display potent cytotoxicity against various tumor cells pretreated with zoledronic acid (Zol). Zol has shown benefits when added to adjuvant endocrine therapy for patients with early-stage breast cancer or to standard chemotherapy for patients with multiple myeloma. Although cd T cells may contribute to this additive effect, the responsiveness of cd T cells from early-stage breast cancer patients has not been fully investigated. In this study, we determined the number, frequency, and responsiveness of Vc2Vd2 T cells from early-and late-stage breast cancer patients and examined the effect of IL-18 on their ex vivo expansion. The responsiveness of Vc2Vd2 T cells from patients with low frequencies of Vc2Vd2 T cells was significantly diminished. IL-18, however, enhanced ex vivo proliferative responses of Vc2Vd2 T cells and helper NK cells from patients with either low or high frequencies of Vc2Vd2 T cells. Treatment of breast cancer patients with Zol alone decreased the number of Vc2Vd2 T cells and reduced their ex vivo responsiveness. These results demonstrate that Zol can elicit immunological responses by cd T cells from early-stage breast cancer patients, but that frequent in vivo treatment reduces Vc2Vd2 T cell numbers and their responsiveness to stimulation.
Introduction
Vc2Vd2 T cells (also termed Vc9Vd2 T cells) recognize phosphoantigens derived from isoprenoid pathways, including isopentenyl diphosphate (IPP) and (E)-4-hydroxy-3-methylbut-2-enyl diphosphate (HMBPP), in an MHC class Tomoharu Sugie and Kaoru Murata-Hirai contributed equally to this work.
I-and MHC class II-independent manner [1] [2] [3] [4] [5] [6] [7] [8] [9] . Vc2Vd2 T cells target and lyse tumor cells that have been treated with nitrogen-containing bisphosphonates (N-BPs), such as pamidronate, zoledronic acid (Zol) and risedronate, in a cd TCR-dependent manner [10] [11] [12] . N-BPs have been used as therapeutic agents for osteoporosis and hypercalcemia of malignancy. The primary target for N-BPs is farnesyl diphosphate synthase (FPPS) whose inhibition leads to the accumulation of its upstream metabolite, IPP [13, 14] . Although the precise molecular mechanism underlying Vc2Vd2 TCR recognition of phosphoantigens presented by tumor cells remains unclear, stimulation of cd T cells has received much attention as a potential therapeutic intervention for infections and malignancies [15, 16] .
Zoledronic acid has recently been tested in clinical trials as an additive therapeutic for early-stage breast cancer and multiple myeloma. In early-stage breast cancer, the addition of Zol to standard therapy improved disease-free survival in estrogen receptor-positive patients in a lowestrogen environment [17] [18] [19] . Zol also had treatment benefits in patients with newly diagnosed multiple myeloma-improving overall survival independently of the prevention of skeletal-related events [20] . Taken together, these studies clearly demonstrate that Zol has a beneficial effect on cancer patients. However, the mechanism by which Zol mediates these effects is still unclear since the effects appear to extend beyond the prevention of skeletalrelated events [20, 21] . This has lead to the proposal that Vc2Vd2 T cells contribute to the observed beneficial effect of Zol in early-stage breast cancer patients [22] . Moreover, adoptive Vc2Vd2 T cell therapy has shown some promise in the treatment of breast cancer with a complete remission achieved in one patient with concurrent hormonal therapy that had previously failed hormonal, radiation, and chemotherapy treatments [23] . To understand the role of Vc2Vd2 T cells in early-stage breast cancer patients treated with Zol and to develop cd T cell treatments for these patients, we have investigated the characteristics of Vc2Vd2 T cells from these patients and have determined the ability of Vc2Vd2 T cells to expand ex vivo and the effect of IL-18 on this expansion.
Materials and methods

Patients
Breast cancer patients (n = 80) were enrolled after institutional review board approval and with written informed consent. Patient characteristics are summarized in Online Resource 1. Early-stage (stage 0, I, or II) breast cancer patients constituted 62/80 (77.5 %) of the patients, whereas late-stage (stage III, IV) patients constituted 18/80 (22.5 %).
Reagents
Zol was purchased from Novartis Pharmaceuticals Corp. (Basel, Switzerland) and converted to its sodium salt using a Na ? form of Dowex 50 W 9 8 (Muromachi Kogyo Kaisha Ltd., Chuo-ku, Tokyo, Japan). Recombinant human IL-18 and IL-2 were kindly provided by GlaxoSmithKline plc (Research Triangle Park, NC) and Shionogi Pharmaceutical Co., Ltd. (Chuo-ku, Osaka, Japan), respectively.
Stimulation of Vc2Vd2 T cells PBMC were purified as described in Online Resource 2. The cells were stimulated with Zol/IL-2 or Zol/IL-2/IL-18 for 2-10 days as described in Online Resource 3.
Flow cytometry and mAbs
Flow cytometric analysis was performed using a FACSCalibur cytometer (Becton-Dickinson, Franklin Lakes, NJ). The following Abs were used: fluorescein isothiocyanate (FITC)-conjugated anti-Vd1 and anti-Vd2 mAbs (Beckman Coulter Inc., Fullerton, CA), phycoerythrin (PE)-conjugated anti-CD3 mAb (BD Biosciences, San Diego, CA), and isotype control Abs (Biolegend, San Diego, CA), and FcR blocking reagent (human, Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). The gating strategy is depicted in Online Resource 2.
Cytokine production PBMC were stimulated with 5 lM of Zol and 100 U/ml of IL-2 in the presence or absence of 100 ng/ml of IL-18. After incubation at 37°C with 5 % CO 2 for 2 days, the culture supernatants were frozen at -80°C overnight. The samples were then thawed and IFN-c and TNF-a cytokine levels determined by ELISA (Peprotech, Rocky Hill, NJ).
Effect of repeated in vivo injections of Zol
A breast cancer patient (stage II) was given 4 mg of Zol twice, 1 month apart. Peripheral blood samples were obtained just before the first injection, 1 month after the first injection, and 1 month after the second injection. PBMC were purified and cultured for 14 days as described in Online Resource 3. The cells before and after culture were stained and analyzed using a FACSCalibur flow cytometer.
Statistical analysis
Correlations between Vd2
? T cell frequencies on day 0 and cell numbers or Vd2
? T cell frequencies on day 10, or between the Vd2 ? T cell frequencies on day 0 and cytokine production on day 2 were examined using Spearman's rank correlation coefficient (q). Paired t test was used to assess the effect of IL-18 on the expansion of Vd2
? T cells and helper NK cells and cytokine productions. A p value of less than 0.05 was considered statistically significant.
Results
The frequency of Vd2
? T cells in breast cancer patients is inversely correlated with age and disease stage ? T cell frequencies of less than 1 % (Fig. 1) . As summarized in Online Resource 1 and Table 1 , the frequency of Vd2
? T cells inversely correlated with the age (p = 0.044) and disease stage (p = 0.001). When stratified by disease stages, there was no significant difference in Vd1
? T cell frequencies between early-and latestage patients (early: 1.4 ± 1.4 %; late: 1.7 ± 2.5 %). In contrast, higher Vd2
? T cell frequencies were observed in early-stage patients compared with late-stage patients (early: 5.9 ± 7.4 %; late: 2.6 ± 2.8 %). Although the proportion of patients whose Vd2
? T cell frequencies were less than 1 % was essentially the same between early-and late-stage patients (early: 21.0 %; late: 22.2 %), a markedly higher proportion of early-stage patients had Vd2
? T cell frequencies of greater than 5.2 % compared with latestage patients (early: 35.5 %; late: 5.6 %). This difference in Vd2
? T cell frequency between early-and late-stage patients suggests that Vc2Vd2 T cells might be immunologically perturbed based on the severity of disease. Besides age and cancer stage, there was no correlation with any other patient background characteristic, with the expression of either the human epidermal growth factor receptor 2 (HER2) or the estrogen receptor (ER), or with the cancer subtype. ? T cell frequencies of 1 % or less expanded poorly. We also analyzed the correlation between the initial Vd2
? T cell frequency and the expansion rate of Vd2 ? T cells. When stratified by the initial Vd2
? T cell frequency, the average expansion rates ± SD were 722 ± 284-fold, 1,610 ± 588-fold, and 3,447 ± 1,823-fold for patients whose initial frequency was \0.5, 0.5-1, and 1-10 %, respectively. This demonstrated that the responsiveness of Vd2
? T cells from patients with low initial frequency was functionally impaired. In addition, the Vd2
? T cells/CD3 ratios after expansion by Zol for 10 days were 38.2 ± 35.3, 83.7 ± 7.5, and 96.9 ± 3.1 %, respectively. Whereas the functional impairment was prominent when the initial frequency was less than 0.5 %, the relatively large SD, 35.3 %, indicated variability in responsiveness among patients with low initial frequency of Vd2
? T cells. Similarly, the production of IFN-c (q = 0.566; p \ 0.01) and TNF-a (q = 0.617; p \ 0.01) also correlated with the initial frequency of Vd2
? T cells (Figs. 3c, d, respectively). The correlation between the initial Vd2
? T cell frequency and the responsiveness of Vd2
? T cells to Zol/IL-2 stimulation was also observed in late-stage breast cancer patients ( Fig. 3 ; open circles).
Effect of IL-18 on the ex vivo expansion of Vc2Vd2 T cells from early-stage breast cancer patients Significant numbers of breast cancer patients had initial Vd2
? T cell frequency of 1 % or less (Fig. 1b) . Based on our findings, for some patients, Zol treatment might not stimulate in vivo Vc2Vd2 T cell expansions and ex vivo expansion of Vc2Vd2 T cells for adoptive immunotherapy would be poor. We previously reported that IL-18 promoted expansion of cd T cells from healthy individuals [24] . Therefore, the effect of IL-18 on the expansion of Vc2Vd2 T cells from breast cancer patients was investigated. Addition of IL-18 to Zol/IL-2 treatment significantly increased the expansion of Vd2
? T cells by 2.7-fold (p = 0.0053) (Fig. 4a ). For example, for three representative breast cancer patients, the addition of IL-18 increased 
cells). Thus, CD3
-cells increased by an average of 10.9-fold (p = 0.0020) (Fig. 4b) . The addition of IL-18 to PBMC stimulated with Zol/IL-2 also increased the production of INF-c by 6.3-fold (p \ 0.0001) and TNF-a by 4.7-fold (p \ 0.0001) (Fig. 4c, d, -cells as NK cells, almost all of these cells expressed NK surface markers including CD56, NKG2D, and CD16, but not monocytic markers such as CD14 (Online Resource 4). We also examined expression of APC-related molecules, such as CD86, CD80, HLA-DR, and HLA-DQ-all were strongly expressed, whereas the expression of NKp44, a positive NK receptor, was downregulated, suggesting that ''helper'' NK cells were expanded along with Vd2
? T cells.
Frequent Zol administration as used in the AZURE trial leads to decreasing blood Vc2Vd2 T cell levels and decreased ability for their ex vivo expansion Some recent clinical trials on early breast cancer patients demonstrated additional clinical benefits when Zol was added to standard cancer therapy [26] . Whereas two trials (the Austrian Breast and Colorectal Cancer Study Group trial-12 (ABCSG-12) [17, 18] and the Zometa-Ferma Adjuvant Synergy Trials (ZO-FAST) [19] ) showed clinical benefits for most patients, another (the Adjuvant Zoledronic Acid to Reduce Recurrence (AZURE) trial [27] ) showed benefits only with postmenopausal women. Besides the increased frequency of chemotherapy [27] , one other important difference between the trials was that the AZURE trial gave Zol every 3 weeks initially for 6 doses and quite frequently thereafter, whereas the ABCSG-12 and ZO-FAST trials gave Zol only every 6 months. Therefore, we examined the effect of in vivo Zol administration on Vd2 ? T cells in breast cancer patients when given at 4 week intervals. The Vd2
? T cell frequency in the peripheral blood of one stage II patient decreased after repeated Zol injection spaced at 1 month interval from 0.79 % prior to therapy to 0.55 % after the first dose, and 0.46 % after the second dose (Fig. 5) . The efficiency of ex vivo Vd2
? T cell expansion also progressively decreased, with Vd2/CD3 ratios of 94.2, 88.7, and 64.0 %, and numbers of Vd2
? cells of 4.00 9 10 8 , 2.68 9 10 8 , 0.08 9 10 8 , respectively. Similar decreases in peripheral blood Vc2Vd2 T cells were noted in four other patients withVd2
? T cell frequencies decreasing from 3.7 to 3.0 % (stage IV), 1.8-1.4 % (stage IV), 0.6-0.3 % (stage IV), and 0.6-0.3 % (stage I). Overall, Vd2
? T cell frequency in the blood decreased an average of 34.4 % for the five patients 1 month after one dose of Zol. These pilot studies suggest that frequent Zol treatments of breast cancer patients leads to decreasing blood Vc2Vd2 T cell levels and decreased ability for ex vivo expansion.
Discussion
Recent clinical trials demonstrate that Zol provides clinical benefits in the treatment of patients with early-stage breast cancer and multiple myeloma, although the contribution of cd T cells to the beneficial effects is unclear [26] . In the present study, we have examined the number, frequency, and responsiveness of peripheral blood cd T cells from patients with breast cancer. The average Vd2
? T cell frequency was significantly higher in early-stage patients compared with late-stage patients (5.9 vs 2.6 %) and slightly higher than healthy donors (4.3 ± 2.2 %). In fact, many breast cancer patients had elevated Vd2
? T cell frequencies with 35.5 % of patients having greater than 5.2 % Vd2 ? T cells (22/62) and 19.4 % (12/62) greater than 10 %. When stratified by patients' background, the frequency of Vd2
? T cells correlated negatively with age and disease stages. These findings further support the hypothesis that Vc2Vd2 T cells are immunologically perturbed by the development of mammary carcinomas. T cells was less than 1 %. Because the proportion of patients with a Vd2 ? T cell frequency of less than 1 % is significantly higher in breast cancer patients than in healthy individuals, it is thus more difficult to expand Vd2 ? T cells from patients. IFN-c and TNF-a cytokine production also correlated with the initial frequency of Vd2
? T cells although somewhat less strongly. This may be because the inhibition of FPPS by Zol also affects other cells in PBMC, such as monocytes and NK cells, and can cause apoptosis that may stimulate cytokine secretion by innate NK cells [28] .
We previously reported that IL-18 enhanced proliferative responses of Vd2
? T cells from healthy donors in response to phosphoantigens [24] . In this study, we examined whether IL-18 could compensate for the low Vd2
? T cell frequencies observed in many breast cancer ? T cell proliferation [24] . In fact, the depletion of CD56
? cells from PBMC resulted in only poor proliferation of Vd2
? T cells [24] . The present study demonstrated that in breast cancer patients this subset can expand to a greater degree than Vd2
? T cells. These cells exhibited a ''helper'' APC phenotype because they expressed the APCrelated molecules, HLA-DQ, HLA-DR, CD86, and CD80. This is consistent with previous reports that NK cells may acquire a ''helper'' phenotype upon exposure to IL-18 [25, 29] . We therefore have termed this subset ''helper'' NK cells. Although ''helper'' NK cells appear to preferentially promote expansion of Vd2 ? T cells under the condition in this study, the precise mechanism underlying the helper function remains to be determined. Because large aggregates of cells are observed in cultures in the presence of Zol/IL-2/IL-18 [24] and because the disruption of adhesion molecule-mediated cell-to-cell contact by anti-LFA-1 mAb greatly reduced the proliferative responses of Vd2 ? T cells [9] , promotion of cell-to-cell contact by IL-18 may play a pivotal role in the marked expansion observed. Interestingly, the CD11c int CD56
? cells tend to lose the expression of CD11c as culture proceeds, and the resulting CD11c -/low
CD56
? cells no longer support the proliferation of Vd2 ? T cells [24] . These findings suggest that IL-18/IL-2 might primarily promote the differentiation and expansion of ''helper'' NK cells, which in turn support the expansion of Vd2
? T cells through the adhesion molecule-mediated interaction. Studies to identify the precursor of this NK subset and its differentiation pathway are ongoing.
While the effect of IL-18 on Vd2 ? T cells is not as marked as that on ''helper'' NK cells, Vd2
? T cells also tend to develop a stronger ''helper'' APC phenotype upon stimulation with phosphoantigens in the presence of given that there is further up-regulation of the expression of APC-related molecules. Because both cell subsets can be considered to be types of innate immune cells and play a crucial role in provoking adaptive immune responses, it is reasonable to assume that ''helper'' NK cells and Vd2
? T cells present classical peptide antigens to adaptive ab T cells, through which effective, highly specific immune reactions take place to eliminate infected cells and malignant tumors [30] . Whereas we focused on the effect of ''helper'' NK cells on Vd2
? T cells in this study, a recent report also suggested that Vd2
? T cells induced robust NKcell-mediated cytotoxicity through CD137 engagement, indicating a cross-talk between NK cells and Vd2
? T cells [31] .
Endogenous production of IL-18 also played a role in Zol/IL-2 responses. Both cell aggregation and cytokine production were impaired by blocking IL-18 signaling, clearly supporting a crucial role of IL-18 in the expansion of Vd2
? T cells [24] . Inhibition of mevalonate pathway by Zol inhibition of FPPS results in the depletion of downstream isoprenoid metabolites, including geranylgeraniol, that in turn is likely to lead to the activation of caspase-1 [32] . Because IL-18 is processed by caspase-1 to become a biologically active species, the exposure of cells to Zol may enhance the production of active IL-18. Although it is ? T cells are negatively affected by frequent Zol treatment [34] [35] [36] . A previous preclinical study showed that the infusion of low-dose IL-2 together with Zol successfully expanded Vc2Vd2 T cells in patients with prostate cancer and breast cancer [37, 38] . Thus, IL-2 or another T cell growth factor is necessary when Zol infusion is used to augment Vd2
? T cells for cancer immunotherapy. Otherwise, Zol infusion will lead to the exhaustion of Vd2
? T cells, and this subset will dwindle to a marginal level where the efficient expansion of Vd2
? T cells is unfeasible. Consistent with these findings, it has been well documented that patients suffer from fever and flu-like symptoms due to the activation of Vd2
? T cells after the initial infusion of N-BP, but that the subsequent infusion of N-BP 1-2 months later does not cause such symptoms [39] .
This loss of Vc2Vd2 T cell function may partially explain the differences observed between the various clinical trials of Zol in early-stage breast cancer patients. Whereas the AZURE trial gave Zol every 3-4 weeks for 6 doses, every 3 months for 8 doses, and then every 6 months [27] , the ABCSG-12 [18] and ZO-FAST [19] trials gave Zol much less frequently-only every 6 months. This long interval between Zol infusion in the ABCSG-12 and ZO-FAST trials may allow partial recovery of Vc2Vd2 T cell immune function. Consistent with this possibility, we found that administration of Zol twice in 2 months in rhesus monkeys caused decreased Vc2Vd2 T cell responsiveness, but that partial recovery of Vc2Vd2 T cell responsiveness was observed in 3 out of 4 monkeys after a rest period of 9 months (C. Jin and C. T. Morita, personal observation). Thus, less frequent Zol infusion may actually be better than intensive Zol therapy at promoting the immunotherapeutic effects of Vc2Vd2 T cells in earlystage breast cancer patients. Less-intensive therapy would also serve to decrease the frequency of osteonecrosis of the jaw, a major side effect of intensive Zol therapy.
Besides direct in vivo administration of Zol, adoptive immunotherapy with Vc2Vd2 T cells expanded ex vivo with either Zol or 2-methyl-3-butenyl diphosphate has shown promise in clinical trials. Complete remissions have been observed after adoptive immunotherapy with Vc2Vd2 T cells in an early-stage breast cancer patient also treated with hormonal suppression therapy [23] and a renal cancer patient with metastatic disease [40] . Our results clearly demonstrate that adoptive immunotherapy with Vc2Vd2 T cells would be feasible for the majority of both early-and late-stage breast cancer patients given that most patients had significant ex vivo expansion of Vc2Vd2 T cells. Moreover, for the *20 % of patients that have Vc2Vd2 T cells less than 1 % which is correlated with poor ex vivo expansion, IL-18 can be shown to augment Vc2Vd2 T cell expansion which may allow immunotherapy even in these patients. The Vc2Vd2 T cells generated by ex vivo expansion have been shown to traffic to tumors in patients as early as 1 h after administration [23] .
In summary, this study provides support for an immunotherapeutic role for Vc2Vd2 T cells in early-stage breast cancer patients. Many breast cancer patients had elevated Vd2
? T cell frequencies and the majority exhibited large ex vivo expansions of Vc2Vd2 T cells that could be augmented further by IL-18. However, the frequent in vivo administration of Zol was detrimental to Vc2Vd2 T cells strongly suggesting that less frequent treatment may be preferable to preserve Vc2Vd2 T cell function and to avoid Zol side effects. This study shows that adoptive immunotherapy with Vc2Vd2 T cells is feasible for the majority of early-and late-stage breast cancer patients. Successful treatment of a breast cancer patient with Vc2Vd2 T cells provides proof-of-concept that Vc2Vd2 T cells can be used for immunotherapy. The challenge will be to optimize Vc2Vd2 T cell immunotherapy and to select the patients most likely to respond.
